Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics

Milestone Pharmaceuticals Inc. (MIST): $1.59

0.01 (+0.63%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

MIST Price/Volume Stats

Current price $1.59 52-week high $4.49
Prev. close $1.58 52-week low $1.33
Day low $1.54 Volume 33,144
Day high $1.60 Avg. volume 191,469
50-day MA $1.84 Dividend yield N/A
200-day MA $2.84 Market Cap 53.24M

MIST Stock Price Chart Interactive Chart >

MIST POWR Grades

  • MIST scores best on the Sentiment dimension, with a Sentiment rank ahead of 83.27% of US stocks.
  • MIST's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • MIST's current lowest rank is in the Growth metric (where it is better than 17.25% of US stocks).

MIST Stock Summary

  • With a year-over-year growth in debt of 1,878.6%, MILESTONE PHARMACEUTICALS INC's debt growth rate surpasses 99.48% of about US stocks.
  • As for revenue growth, note that MIST's revenue has grown 200% over the past 12 months; that beats the revenue growth of 97.37% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MIST comes in at -81.5% -- higher than that of just 5.09% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MILESTONE PHARMACEUTICALS INC are ENVX, CRNX, FLNC, SWAV, and VRCA.
  • Visit MIST's SEC page to see the company's official filings. To visit the company's web site, go to www.milestonepharma.com.

MIST Valuation Summary

  • In comparison to the median Healthcare stock, MIST's price/earnings ratio is 103.09% lower, now standing at -0.9.
  • MIST's price/sales ratio has moved NA NA over the prior 56 months.

Below are key valuation metrics over time for MIST.

Stock Date P/S P/B P/E EV/EBIT
MIST 2023-12-29 12.4 2.0 -0.9 -1.7
MIST 2023-12-28 13.2 2.1 -1.0 -1.7
MIST 2023-12-27 14.0 2.2 -1.1 -1.8
MIST 2023-12-26 14.8 2.3 -1.1 -1.9
MIST 2023-12-22 21.4 3.4 -1.6 -2.4
MIST 2023-12-21 20.9 3.3 -1.6 -2.3

MIST Price Target

For more insight on analysts targets of MIST, see our MIST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.60 Average Broker Recommendation 1.4 (Strong Buy)

Milestone Pharmaceuticals Inc. (MIST) Company Bio


Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.


MIST Latest News Stream


Event/Time News Detail
Loading, please wait...

MIST Latest Social Stream


Loading social stream, please wait...

View Full MIST Social Stream

Latest MIST News From Around the Web

Below are the latest news stories about MILESTONE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIST as an investment opportunity.

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.

Yahoo | December 27, 2023

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Upon preliminary review, the FDA determined that the NDA, submitted in October 2023, was not sufficiently complete to p

Yahoo | December 26, 2023

Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutions

Key Insights Significant control over Milestone Pharmaceuticals by individual investors implies that the general public...

Yahoo | December 26, 2023

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time.

Yahoo | November 21, 2023

Milestone Pharmaceuticals Third Quarter 2023 Earnings: US$0.45 loss per share (vs US$0.34 loss in 3Q 2022)

Milestone Pharmaceuticals ( NASDAQ:MIST ) Third Quarter 2023 Results Key Financial Results Net loss: US$15.1m (loss...

Yahoo | November 15, 2023

Read More 'MIST' Stories Here

MIST Price Returns

1-mo 3.25%
3-mo -42.39%
6-mo -44.21%
1-year -53.10%
3-year -79.62%
5-year N/A
YTD -4.79%
2023 -57.83%
2022 -39.54%
2021 -2.24%
2020 -58.15%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!